Περίληψη:
Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving targeted and immune-based treatments for melanoma. After decades of unsuccessful attempts to finding a more effective cure in the treatment of melanoma now we have several drugs active in melanoma. The possibility to use these drugs in combination to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy represent new concepts and approaches in the clinical management of melanoma. The third " Melanoma Research: " A bridge from Naples to the World" meeting, shortened as " Bridge Melanoma Meeting" took place in Naples, December 2 to 4th, 2012. The four topics of discussion at this meeting were: advances in molecular profiling and novel biomarkers, combination therapies, novel concepts toward integrating biomarkers and therapies into contemporary clinical management of patients with melanoma across the entire spectrum of disease stage, and the knowledge gained from the biology of tumor microenvironment across different tumors as a bridge to impact on prognosis and response to therapy in melanoma. This international congress gathered more than 30 international faculty members who in an interactive atmosphere which stimulated discussion and exchange of their experience regarding the most recent advances in research and clinical management of melanoma patients. © 2013 Ascierto et al.; licensee BioMed Central Ltd.
Συγγραφείς:
Ascierto, P.A.
Grimaldi, A.M.
Acquavella, N.
Borgognoni, L.
Calabrò, L.
Cascinelli, N.
Cesano, A.
Del Vecchio, M.
Eggermont, A.M.
Faries, M.
Ferrone, S.
Fox, B.A.
Gajewski, T.F.
Galon, J.
Gnjatic, S.
Gogas, H.
Kashani-Sabet, M.
Kaufman, H.L.
Larkin, J.
Lo, R.S.
Mantovani, A.
Margolin, K.
Melief, C.
McArthur, G.
Palmieri, G.
Puzanov, I.
Ribas, A.
Seliger, B.
Sosman, J.
Suenaert, P.
Tarhini, A.A.
Trinchieri, G.
Vidal-Vanaclocha, F.
Wang, E.
Ciliberto, G.
Mozzillo, N.
Marincola, F.M.
Thurin, M.
Λέξεις-κλειδιά:
alpha interferon; biological marker; cancer vaccine; celecoxib; cisplatin; cobimetinib; cytotoxic T lymphocyte antigen 4 antibody; dabrafenib; dacarbazine; fotemustine; granulocyte macrophage colony stimulating factor vaccine; interferon; interleukin 2; ipilimumab; melanoma antigen 3; melanoma antigen 3 vaccine; melphalan; onamelatucel L; paclitaxel; palbociclib; peginterferon alpha2b; placebo; talimogene laherparepvec; temozolomide; ticilimumab; trametinib; unclassified drug; unindexed drug; vaccinia vaccine; vemurafenib; vinblastine, adoptive immunotherapy; area under the curve; bone marrow toxicity; cancer diagnosis; cancer immunotherapy; cancer inhibition; cancer radiotherapy; cancer research; cancer resistance; cancer staging; cancer surgery; colorectal cancer; conference paper; cutaneous melanoma; drug approval; drug dose escalation; drug efficacy; drug eruption; drug fever; drug mechanism; drug megadose; electrochemotherapy; fatigue; human; immune system; immunomodulation; liver cancer; maximum plasma concentration; melanoma; metastatic melanoma; myalgia; neutropenia; nonhuman; overall survival; photosensitivity; prognosis; progression free survival; recurrence free survival; side effect; skin carcinoma; thrombocytopenia; treatment response; tumor microenvironment; unspecified side effect, Animals; Antineoplastic Agents; Clinical Trials as Topic; Gene Expression Regulation, Neoplastic; Humans; Medical Oncology; Melanoma; Mutation; Prognosis; Skin Neoplasms; Tumor Markers, Biological
